CorMedix Locks Down All Top Dialysis Providers as REZZAYO Catalyst Looms

CorMedix (CRMD) delivered a second quarter that crystallized its evolution from a single-product biotech into a diversified commercial-stage pharmaceutical company. The most striking development was the signing of a multi-year commercial supply agreement with the last major U.S. dialysis provider, giving CorMedix contracts with all five of the top dialysis organizations (LDOs). This validates DefenCath's clinical value proposition amid the challenging post-TDAPA reimbursement landscape. Revenue reached $101.9 million, adjusted EBITDA hit $58.7 million, and management raised full-year adjusted EBITDA guidance to $125–$140 million.

Commercial Milestone: All Top 5 LDOs Signed

The new LDO agreement is not just a symbolic win; it has immediate operational implications. As CEO Joe Todisco explained, “With this agreement, CorMedix now has commercial supply agreements in place with all 5 of the top dialysis providers in the U.S.” — Joseph Todisco, Chairman and Chief Executive Officer · 2026-08-13 The newly signed LDO has placed an initial order and will begin a pilot in Q3, with potential expansion in 2027. Management noted the pilot could cover a couple hundred clinics, but they are intentionally cautious about projections. This is a new LDO that has been a persistent theme in earnings calls, and finally breaking through is a significant de-risking event for the franchise. The agreement also provides momentum for post TDAPA strategy, ensuring utilization continuity as reimbursement shifts.

The commercial execution extends beyond contracts. The company is actively working on Medicare Advantage contracting, which management views as the next major growth lever. While not included in 2026 guidance, progress on this front could open a larger patient pool. Additionally, the growing body of real-world evidence – including upcoming presentations at ASN and IDWeek – strengthens the value proposition for both providers and payers.

Pipeline Progress: REZZAYO sNDA on Track

The pipeline narrative is equally compelling. The company is preparing to submit a supplemental new drug application (sNDA) for REZZAYO in the prophylaxis of invasive fungal disease, following positive Phase III ReSPECT data. As Todisco noted, “We announced this morning that we anticipate the submission of the sNDA for REZZAYO in prophylaxis in the third quarter of this year.” — Joseph Todisco, Chairman and Chief Executive Officer · 2026-08-13 This is a sNDA for REZZAYO that could expand the label and significantly increase the total addressable market. Management expects FDA action in the first half of 2027 and is already building commercial infrastructure, adding 15–20 positions in the back half of the year.

The commercial readiness is also supported by real world evidence from partners like U.S. Renal Care and Fresenius, which have publicly highlighted DefenCath's clinical and economic benefits. During the Q&A, when asked about the pilot scale, Todisco replied, “we've shifted initial order. We think it's a couple hundred clinics.” — Joseph Todisco, Chairman and Chief Executive Officer · 2026-08-13 This cautious optimism reflects the company's disciplined approach to execution.

Financial Performance: Profitability Inflection

Financially, the second quarter was robust. Revenue grew 157% year-over-year (driven by DefenCath plus the recently acquired Melinta portfolio). The company posted a net income of $26 million and generated $128.6 million in operating cash flow for the first half of 2026. This profitability is a stark departure from the past, as illustrated by the Total Revenue trend which jumped from under $1M in 2024 to over $100M in 2025–2026. The raised EBITDA guidance underscores management's confidence. As Todisco stated in prepared remarks:

We are reaffirming our full-year 2026 revenue guidance with a range of $325 million to $345 million, and raising our full-year adjusted EBITDA guidance to a new range of $125 million to $140 million.

While the fundamentals are strong, it's important to note that the recent 90-day price trend shows a +13.3% appreciation, though the full-history drawdown remains deep. The market is rewarding the execution but still pricing in substantial risk around the TDAPA transition and pipeline uncertainty.

Looking back at prior calls, this pivot is consistent with management's stated strategy. In May 2026, Todisco noted, “For 2027, as we mentioned in the script, we expect to see appreciation in the net selling price as we move into 2027 compared to that third and fourth quarter.” — Joseph Todisco, Chairman and Chief Executive Officer · 2026-05-14 That expectation is now supported by the contract amendments signed with major customers. Similarly, the emphasis on real-world evidence was previewed in the November 2025 call: “I think the real-world evidence data is going to be critical, right? And that should be – it's interim midpoint data available by the end of the year.” — Joseph Todisco, Chief Executive Officer · 2025-11-12

What changed this quarter is the culmination of these efforts: full LDO coverage, a concrete REZZAYO submission timeline, and raised profitability guidance. The company is no longer a speculative launch story but a commercial business with a pipeline catalyst. For investors, the key question is whether DefenCath can maintain utilization post-TDAPA and whether REZZAYO can replicate the commercial success. With all top providers now contracted, the foundation for a durable franchise is in place.